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Abstract 
The landscape of new psychoactive substances (NPS) is constantly evolving, with new compounds 
entering the illicit drug market at a continuous pace. Of these, opioid NPS form a threat given their 
high potency and prevalence. Whereas previously, the use of fentanyl and fentanyl derivatives was the 
main point of attention, legislations have reacted accordingly, which may have been a driving force 
towards the (ab)use of alternative µ-opioid receptor (MOR) agonists. In contrast to fentanyl 
(analogues), details on these novel non-fentanyl opioid NPS are scarce. We investigated the biological 
activity of a panel of 11 ‘alternative’, newly emerging MOR agonists (2-methyl-AP-237, AP-237, 
bromadol, brorphine, butorphanol, isotonitazene, mitragynine, 7-OH-mitragynine, MT-45, 
piperidylthiambutene and tianeptine) using two closely related in vitro MOR activation bio-assays, 
monitoring either G protein (mini-Gi) or β-arrestin2 (βarr2) recruitment. Activity profiles were 
obtained for all tested compounds, with values for potency (EC50) ranging from 1.89 nM (bromadol) to 
>3 µM (AP-237 and tianeptine). Bromadol, brorphine, isotonitazene, piperidylthiambutene and 
tianeptine had the highest efficacy (Emax) values, exceeding that of the reference compound 
hydromorphone ≥1.3-fold (βarr2 assay) and >2.6-fold (mini-Gi assay). Information on the recruitment 
of two distinct signaling molecules additionally enabled evaluation of biased agonism, none of the 
evaluated opioids being significantly biased. Taken together, this study is the first to systematically 
investigate the in vitro biological activity of a diverse panel of emerging non-fentanyl opioid NPS at 
MOR. Given the known danger of (fatal) intoxications with many opioid NPS, it is important to 
continuously monitor and characterize newly emerging compounds.  
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Introduction 
 
The last decade has seen a dynamic growth in the availability and use of new psychoactive substances 
(NPS) across the globe. By definition not controlled by the United Nations international drug control 
conventions of 1961 and 1971 (UNODC 2020), these newly misused substances comprise a wide variety 
of drugs, including synthetic cannabinoid receptor agonists, stimulants and opioids. NPS are typically 
labeled as “legal highs”, “research chemicals” and “not for human consumption”, promoting their 
allegedly legal status as easily available alternatives for traditional drugs of abuse. The appearance of 
over 730 NPS in Europe since 1997 has truly added a new dimension to the illicit drug market and 
increasingly challenges the traditional approaches to drug monitoring and control (EMCDDA 2019d; 
EMCDDA and Europol 2019; Peacock et al. 2019).  
 
Although currently representing a relatively small share of Europe’s NPS market, new synthetic opioids 
(NSOs) form a particular menace to public health, owing to their high potency and prevalence 
(EMCDDA 2019d; EMCDDA and Europol 2019). Many of these newly abused opioids were once pursued 
by the pharmaceutical industry for their potential as narcotic analgesics. However, owing to unwanted 
pharmacological side effects and addiction liability, their development was often abandoned before 
progressing to clinical trials. Nowadays, the published patents and synthesis routes stemming from 
this research are being pirated by underground chemists to diversify the recreational drug market 
(Meyer 2016; Salle et al. 2019; Sharma et al. 2019). Other synthetic opioids, such as fentanyl and 
butorphanol, are effectively used in human or veterinary medicine whilst also being abused for their 
opioid effects. Already in the early 1980s, the first illicitly produced fentanyl analogues, including α-
methylfentanyl and 3-methylfentanyl, were being sold to heroin users on the US west coast (Armenian 
et al. 2018; Ayres, Starsiak, and Sokolay 1981; Jannetto et al. 2019). Starting slowly, but then gradually 
gaining pace, the past decade has seen a new ‘wave’ of NSOs. Amongst the first to appear for online 
sale in this new wave were AH-7921 in 2012 and MT-45 in 2013. As from 2014, several compounds of 
the ‘U series’ (originally developed in the ‘70s by the Upjohn Company) became increasingly detected, 
with U-47700 being one of the most prevalent non-fentanyl NSOs (Blanckaert & Cannaert et al. 2020; 
Sharma et al. 2019). Between 2012 and 2018, however, the majority of NSOs hitting the drug market 
remained fentanyl analogues (Cannaert & Ambach et al. 2018; Evans-Brown, Gallegos, and Christie 
2018; Jannetto et al. 2019). Being increasingly confronted with the severe risk of fatal poisoning 
following the use of these substances, important efforts were made to counter this trend (Bao et al. 
2019; DEA 2018). The introduction of a new legislation in China in 2018 was probably the most 
impactful measure, as the number of new fentanyl analogues started to decrease drastically from 2018 
onwards (Bao et al. 2019; Blanckaert & Cannaert et al. 2020). However, as exemplified by the recent 
emergence of brorphine, which could be considered a fentanyl analogue, drug designers still manage 
to find loopholes in existing legislations, even when these are ‘generic’ and thus aiming at covering a 
very wide range of analogues (Verougstraete & Vandeputte et al., under review) (Belgisch Staatsblad 
2017; DEA 2018).  
 
As a response to the recent changes in (inter)national control measures targeting fentanyl analogues, 
there has been a trend of non-fentanyl opioids (re)appearing on the recreational drug market (e.g. 2-
Me-AP-237, isotonitazene) (Blanckaert & Cannaert et al. 2020; Sharma et al. 2019). While extensive 
literature has been published on the pharmacology and toxicology of fentanyl, fentanyl derivatives and 
some of the early non-fentanyl opioids (Jannetto et al. 2019; Prekupec, Mansky, and Baumann 2017; 
Sharma et al. 2019; Vasudevan et al. 2020), many of these somewhat obscure, newly emerging opioids 
have received considerably less attention. However, the increasing amount of case reports on 
(sometimes fatal) intoxications involving these drugs, stresses the danger of their use. As a better 
insight into the pharmacology of NSOs may allow to prioritize international and legislative efforts 
towards controlling (variants of) these emerging drugs, we investigated the pharmacological profile of 
11 non-fentanyl opioid NPS (Figure 1). The compounds in this panel were chosen based on their 
structural diversity as non-fentanyl µ-opioid receptor (MOR) agonists and their recent and/or emerging 
appearance on the recreational drug market (Arillotta & Schifano et al. 2020; Blanckaert & Cannaert 
et al. 2020; Sharma et al. 2019; Ventura, Carvalho, and Dinis-Oliveira 2018). Although brorphine could, 
in essence, be considered a structural analogue of fentanyl (Verougstraete & Vandeputte et al., under 
review), it currently falls outside the scope of generic legislations aiming at covering fentanyl 
derivatives (Belgisch Staatsblad 2017; DEA 2018) and was therefore included in this study as well. 
While several opioid receptors have been identified, the receptor of focus in this study was MOR, as 
this is the main target for most of the potent analgesics currently in use (Al-Hasani & Bruchas 2011; 
Pasternak & Pan 2011). Efficacy and potency values of the 11 compounds were studied using two 
closely related MOR activation assays monitoring either G protein or β-arrestin 2 (βarr2) recruitment. 
In addition, information on these two signaling pathways enabled the evaluation of potential biased 
agonism of these compounds at MOR, a concept that is now being increasingly debated for opioids 
(Gillis & Gondin et al. 2020). 
 
  
Materials & Methods 
a. Chemicals and reagents 
(-)-Mitragynine (7) was obtained from Chiron (Trondheim, Norway). 2-methyl-AP-237 HCl (1), AP-237 
HCl (2), trans-bromadol (3), brorphine HCl (4), isotonitazene (6), 7-OH-mitragynine (8) and 
piperidylthiambutene HCl (10) were purchased from Cayman Chemical Company (Ann Arbor, 
Michigan, US). Butorphanol (5), MT-45 (9) (as racemic mixture) and tianeptine (11) were kind gifts from 
Prof. V. Auwärter (University of Freiburg) and were originally obtained from Cerilliant (Round Rock, 
Texas, US), Lipomed AG (Arlesheim, Switzerland) and Cayman Chemical Company (Ann Arbor, 
Michigan, US), respectively. Hydromorphone (A) was purchased as hydrochloride salt from Fagron 
(Nazareth, Belgium). Fentanyl (B) was obtained from LGC Chemicals (Wesel, Germany). Dulbecco’s 
modified Eagle’s medium (DMEM; GlutaMAX™), Opti-MEM® I reduced serum medium, penicillin-
streptomycin (5 000 U/mL) and amphotericin B (250 µg/mL) were obtained from Thermo Fisher 
Scientific (Pittsburg, PA, USA). Fetal bovine serum (FBS) and poly-D-lysine were supplied by Sigma 
Aldrich (Overijse, Belgium). The Nano-Glo® Live Cell Assay system (containing the Nano-Glo® Live Cell 
Substrate and Nano-Glo® LCS Dilution Buffer) was procured from Promega (Madison, WI, USA). 
 
b. Determination of in vitro biological activity at the µ-opioid receptor (MOR)  
The biological activity of 11 non-fentanyl opioid NPS was evaluated using two distinct, previously 
reported, cell-based receptor activation assays (Cannaert et al. 2018; Vasudevan et al. 2020). The 
sensitivity and specificity of these systems was previously evaluated using a wide range of opioids 
(Cannaert et al. 2018; Vasudevan et al. 2020) and the system has since been successfully applied in 
different studies (Blanckaert & Cannaert et al. 2020; Cannaert & Ambach et al. 2018; Cannaert et al. 
2020; Gampfer et al. 2020). The assays are based on the functional complementation of a split 
nanoluciferase (NanoLuc Binary Technology®, Promega). In the assays, activation of human MOR, 
fused to one part of the nanoluciferase, leads to recruitment of either βarr2 (in the presence of co-
expressed G protein-coupled receptor kinase 2, GRK2) or mini-Gi (GTPase domain of the Gαi subunit), 
fused to the other part. This results in functional complementation of the nanoluciferase, restoring its 
enzymatic activity and allowing the generation of a measurable bioluminescent signal upon addition 
of the substrate furimazine.  
Human embryonic kidney (HEK) 293T cells stably expressing either the MOR-βarr2-GRK2 (further 
referred to as MOR-βarr2) or MOR-mini-Gi system were maintained in a humidified atmosphere 
containing 5% CO2 in DMEM (GlutaMAX™) supplemented with 10% heat-inactivated FBS, 100 IU/mL 
penicillin, 100 mg/L streptomycin and 0.25 mg/L amphotericin B. The stability of the cell lines was 
routinely monitored by flow cytometric analysis of co-expressed markers (Vasudevan et al. 2020). One 
day prior to the experiments, cells expressing either MOR-βarr2 or MOR-mini-Gi were seeded on poly-
D-lysine coated 96-well plates at 5 x 104 cells/well. After overnight incubation, the cells were washed 
twice with Opti-MEM® I reduced serum medium to remove residual FBS. Next, 90 µL Opti-MEM® I was 
added to the washed wells. Nano-Glo® Live Cell reagent, a non-lytic detection reagent containing the 
cell-permeable furimazine, was prepared by 20-fold dilution of Nano-Glo® Live Cell substrate with 
Nano-Glo® LCS Dilution buffer. Twenty-five µL of the reagent solution was added to each well. Next, 
the plate was placed into a TriStar2 LB 942 luminometer (Berthold Technologies GmbH & Co., Bad 
Wildbad, Germany). Luminescence was continuously monitored until stabilization of the signal (10-15 
minutes). Subsequently, 20 µL of 6.75x concentrated stock solutions in Opti-MEM®/MeOH was added 
and luminescence was monitored for 120 minutes. All compounds were initially tested in 
concentrations ranging between 10 pM and 10 µM. If maximal receptor activation was not reached 
with 10 µM, concentrations up to 100 µM were evaluated. Hydromorphone was selected as a 
reference agonist based on previous studies (Blanckaert & Cannaert et al. 2020; Vasudevan et al. 2020) 
and appropriate solvent controls were included in all experiments. FACS-sorted (Fluorescence-
Activated Cell Sorting) stably transduced cells were used, offering the advantage that this reduces 
assay variability, as opposed to when using transiently transfected cells. Every experiment was 
performed at least in triplicate (n = 3), with duplicates run for each concentration within an 
experiment. This approach has proven to yield robust results (Janssens et al. 2020; Vasudevan et al. 
2020). Data points were excluded for the highest concentration of agonist when the signal showed a 
reduction of 20% or more compared to the signal obtained for the next dilution (high concentrations 
probably leading to cell toxicity and/or generating a higher, but narrower peak, leading to lower areas 
under the curve (AUC)). The complete dataset (1476 data points) was screened for outliers using the 
Grubbs test, which resulted in a total of ten outliers that were subsequently omitted from the dataset. 
The βarr2 data for brorphine (4) and MT-45 (9) were also reported in Verougstraete & Vandeputte et 
al. (under review) and Cannaert & Hulpia et al. (2020), respectively. Curve fitting and statistical 
analyses for the experiments were performed using GraphPad Prism 8 software (San Diego, CA, USA). 
Absolute luminescence signals were corrected for solvent controls and inter-well variability before 
concentration-responses (AUC values) were normalized to the maximum response of the reference 
compound hydromorphone (arbitrarily set at 100%). A non-linear regression model (three-parameter 
logistic regression) was fitted to the normalized responses, yielding measures of potency (EC50) and 
efficacy (Emax), the latter relative to hydromorphone. 
 
 
c. Calculation of pathway bias  
Pathway bias was calculated as previously described. Also here, hydromorphone was used as an 
unbiased reference compound (Vasudevan et al. 2020; Winpenny, Clark, and Cawkill 2016). In a first 
step, Equation (1) was used to calculate the ∆log(Emax/EC50) for every compound (A = test compound, 
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The average ∆∆log(Emax/EC50) (coined ‘bias factor’) was calculated from three independent 
experiments, each performed in duplicate, and was plotted together with the standard error of the 
mean (SEM) for each compound. In line with previous work from our group (Janssens et al. 2020; Pottie 
et al. 2020; Vasudevan et al. 2020; Wouters et al. 2020), statistical analysis was carried out by non-
parametric one-way ANOVA (Kruskal-Wallis), followed by post hoc Dunn’s multiple comparison test to 
examine significant differences between the reference hydromorphone and each of the different 





Activation profiles were obtained for all tested compounds (Figure 2). Efficacies (Emax) and potencies 
(EC50) were calculated and can be found in Table 1. For AP-237 (2) and tianeptine (11), maximal 
receptor activation could not be reached in all assays due to the relatively weak agonism displayed by 
these compounds, with cellular toxicity at high concentrations. For butorphanol (5) and mitragynine 
(7), the partial agonism (relative to hydromorphone) led to very wide 95% confidence intervals, 
particularly in the MOR-mini-Gi assay.  
 
The most potent compound in terms of both βarr2 and mini-Gi recruitment was bromadol (3), with an 
EC50 of 1.89 nM (95% confidence interval (CI) 1.23-2.93 nM) for βarr2 and 3.04 nM (95% CI 1.48-6.28 
nM) for mini-Gi. No plateau in response was observed for AP-237 (2) (βarr2 and mini-Gi assays) and 
tianeptine (11) (mini-Gi assay), hence for these compounds no Emax and only ambiguous EC50 values 
could be derived (the latter in the µM range) in the respective assays. In both assays, butorphanol (5), 
mitragynine (7) and 7-OH-mitragynine (8) were partial agonists compared to hydromorphone (A). All 
other compounds were more efficacious than hydromorphone in activating MOR, the efficacy of 
bromadol (3), brorphine (4), isotonitazene (6), piperidylthiambutene (10) and tianeptine (11) 
exceeding that of hydromorphone ≥1.3-fold and >2.6-fold in the βarr2 and mini-Gi assay, respectively. 
With the single exception of butorphanol (5), higher Emax values were found in the mini-Gi recruitment 
assay, the difference between both assays being most pronounced (up to 3-fold) for the most potent 
compounds.  
 
The highly similar set-up of the employed MOR activation assays (only differing in the nature of the 
recruited signal transduction molecule) also allowed the assessment of biased agonism of the studied 
compounds at MOR (with the exception of AP-237 (2) and tianeptine (11), for which Emax values could 
not be derived in all assays). Figure 3 depicts the quantitative bias plot, in which the level of bias is 
plotted as Δlog(Emax/EC50)βarr2 - Δlog(Emax/EC50)mini-Gi ± SEM. None of the studied compounds showed 




This study reports the in vitro pharmacological characterization of 11 emerging non-fentanyl opioid 
NPS. Several of these have been used in the past for research purposes but were never marketed (e.g. 
isotonitazene, MT-45), whereas others, such as butorphanol (e.g. Beforal®/Torbugesic®) or tianeptine 
(e.g. Stablon®/Coaxil®), remain available as prescription drugs in some countries. Recently, these 
compounds have started to emerge on the recreational drug market for their opioid activity. At the 
time of writing, only a limited number of studies, deploying a variety of different assays (discussed 
further), have reported in vitro pharmacological data for the compounds evaluated here. In fact, to the 
best of our knowledge, no in vitro efficacy and potency values have been described before for AP-237 
(2), bromadol (3) and piperidylthiambutene (10).  
 
By reviewing the limited literature on what is already known, the findings in this study illustrate the 
difficulty in comparing data obtained via different assays using various reference compounds. This calls 
to attention the need for in vitro assay standardization across laboratories and the inclusion of relevant 
comparator compounds with known pharmacology (e.g. fentanyl). Although this in vitro study does 
not provide receptor binding affinity data and is limited to evaluating the compounds’ responses at 
MOR, it pioneers in the systematic, comparative evaluation of a diverse panel of emerging opioid NPS 
by means of two highly similar, yet distinct, receptor activation assays monitoring either β-arrestin 2 
or mini-Gi recruitment to activated MOR. The set-up of these assays offers several advantages over 
other assays. First, minimally-sized fusion proteins are involved (with two parts of a split nanoluciferase 
fused to the partnering molecules), aimed at minimally interfering with normal recruitment to the 
activated receptor. Second, a receptor-proximal event is monitored, i.e. the recruitment of either β-
arrestin 2 or mini-Gi to activated MOR. This offers the advantage of minimal signal amplification, 
allowing to make a distinction between partial and full agonists. Assays monitoring a more 
downstream event, on the other hand, may lead to ambiguous results as the maximal signal may 
already be obtained in the absence of full receptor activation (also referred to as ‘receptor reserve’) 
(Gillis & Gondin et al. 2020; Wouters et al. 2019). These features are particularly relevant, as it was 
recently hypothesized that the intrinsic efficacy (Emax) of MOR agonists is inversely correlated with their 
therapeutic window (Benredjem & Gallion et al. 2019; Gillis & Gondin et al. 2020; Wolff et al. 2012). In 
the study by Gillis & Gondin et al. (2020), high efficacy MOR agonists such as fentanyl were found to 
have a very narrow index of therapeutic effect versus respiratory depression in in vivo mouse studies, 
this respiratory depression arguably being the most important cause of death following opioid 
intoxication. With this in mind, the pharmacological data obtained here may allow to direct and 
prioritize scheduling efforts towards those compounds which presumably pose the highest risk to 
users, i.e. those with the highest intrinsic efficacy. In the set we evaluated, these are bromadol (3), 
brorphine (4), isotonitazene (6), piperidylthiambutene (10) and tianeptine (11), although the potency 
of the latter two is moderate to weak, respectively, presumably requiring high doses. Furthermore, as 
also discussed further, it should be stressed that in vitro data can never fully predict the eventual in 
vivo effects an individual might experience from using research chemicals. 
 
The minimal methodological differences between both employed MOR activation assays additionally 
rendered this study highly suitable to assess biased agonism at MOR. In line with recently published 
work studying a diverse panel of NSOs (mainly fentanyl analogues) (Vasudevan et al. 2020), none of 
the evaluated compounds showed statistically significant biased agonism (compared to 
hydromorphone). For a thorough discussion on the highly debated concept of opioid agonism at MOR, 
the reader is referred to recent work by Gillis & Gondin et al. (2020) and by Vasudevan et al. (2020). 
 
As is the case for many of the newly abused synthetic opioids, 2-methyl-AP-237 (1) was originally 
patented in the 1980s for its analgesic activity (Furlan 1985). The first evidence of 2-methyl-AP-237 
appearing on the NPS market dates from the first half of 2019 (NFL Ljubljana 2019a). It was formally 
notified to the EU Early Warning System (EWS) in April 2019 (EMCDDA 2019a) and was found in seized 
material in the US later that year (Krotulski, Fogarty, and Logan 2019a). So far, in 2020, 2-methyl-AP-
237 has been identified 3 times in the US (Krotulski, Mohr, and Logan 2020). A recent in vitro study 
reported an EC50 value of 568 nM using AequoScreen® (Perkin Elmer) recombinant CHO-K1 cells 
expressing human MOR (Aklagarmyndigheten 2019; personal communication with Prof. Dr. Henrik 
Green). We found about four times lower potencies for 2-methyl-AP-237 (EC50 = 2229 nM for both 
βarr2 and mini-Gi) corresponding with a 68-156 times lower potency than that of fentanyl. One month 
after the formal notification of 2-methyl-AP-237, also a desmethyl derivative, AP-237 (2), was notified 
to the EU EWS (EMCDDA 2019b) and was later seized in the US (Krotulski, Fogarty, and Logan 2019b). 
Also known as bucinnazine, AP-237 has been evaluated for its analgesic activity in several studies since 
the early 1970s (Carrano et al. 1975; Carrano, Kimura, and McCurdy 1975; Irikura et al. 1968; Nishimura 
et al. 1970), including one study indicating its potential for dependence (Tao and Wang 1986). Since 
then, it has been used primarily as an analgesic in China (Tao and Wang 1986; Zang 1999). To the best 
of our knowledge, this study is the first to report in vitro biological activity data for AP-237 at MOR. 
With EC50 values in the micromolar range, it is estimated to be 3.5 to 13 times less potent than 2-
methyl-AP-237. Yet another analogue in this series, para-methyl-AP-237, was very recently identified 
in the US (Krotulski, Fogarty, and Logan 2020). It remains to be evaluated whether the low potencies 
observed for 2-methyl-AP-237 and its desmethyl derivative also become apparent for this compound, 
as well as for other analogues in this series that are likely to appear. 
 
Bromadol (3), also referred to as BDPC (trans-4-(p-bromophenyl)-4-(dimethylamino)-1-
phenethylcyclohexanol), was amongst the most potent and efficacious compounds studied here. Using 
a standard mouse hot plate assay, Liu et al. (2003) previously suggested that the analgesic potency of 
bromadol may be around 2.9 times that of fentanyl (Sharma et al. 2019). The herein reported in vitro 
potencies for βarr2 and mini-Gi recruitment echo this, as the EC50 values for bromadol were 7.6- and 
10.8-fold lower than those obtained for fentanyl using the same respective assays. However, as 
discussed further, it remains difficult to directly compare in vivo analgesic potency to in vitro potency 
values. Interestingly, the in vivo antinociceptive potency reported by Liu et al. (2003) was greater than 
what may be expected based on opioid receptor binding affinity data (Sharma et al. 2019). Although 
determination of binding affinity was outside the scope of the current study, the high in vitro efficacy 
and potency at MOR reported here, may provide an explanation for this.  
 
Brorphine (4) has been reported to circulate in the American Midwest since the second half of 2019 
(NFLIS 2019) and has been a topic in online drug user discussions for quite some time. Very recently, 
brorphine was identified in Belgium in a powder and in the serum of a patient seeking medical help for 
detoxification (Verougstraete & Vandeputte et al., under review). Kennedy et al. (2018) previously 
evaluated brorphine within a series of MOR agonists with purported high signaling bias. Using 
commercially available βarr2 enzyme fragment complementation (PathHunter®, DiscoverX) and 
(35S)GTPγS assays, the authors reported EC50 values of 182 ± 42 nM and 4.8 ± 0.41 nM for βarr2 and G 
protein recruitment, respectively (Kennedy et al. 2018). Following operational analysis with DAMGO 
as an unbiased reference compound, these authors concluded that brorphine showed a certain degree 
of bias towards G protein recruitment (Kennedy et al. 2018). Interestingly, in our study, the 
pharmacological profile of brorphine was markedly different. Not only was brorphine not significantly 
biased compared to hydromorphone, it was also found to be more potent at recruiting βarr2 – with an 
EC50 of 31.1 nM approaching the potency of fentanyl - than G protein (EC50 = 106 nM for mini-Gi). In 
contrast to the assays used by Kennedy et al. (2018), our assays are maximally similar and do not differ 
in terms of signal amplification – as also suggested by Gillis & Gondin et al. (2020), this may allow a 
better assessment of intrinsic bias. 
 
Butorphanol (5) is available on the market in several countries, be it for human (e.g. Beforal®) or 
veterinary (e.g. Torbugesic®) use. Therapeutic indications include moderate to severe migraine and 
anesthesia (WHO 2006). Reports of butorphanol abuse are generally related to misuse of the 
prescription drug (e.g. excessive prescription refill, doctor shopping) (WHO 2006). It was first notified 
as an NPS to the EU EWS in December 2013 after a seizure of the powder in Denmark (Blanckaert 2011; 
EMCDDA and Europol 2013). The potency (low-nM range; comparable to fentanyl) of this partial 
agonist in our MOR-mini-Gi assay is in line with findings previously obtained using (35S)GTPγS and 
forskolin-stimulated cAMP accumulation assays in rat and murine MOR, respectively (Emmerson et al. 
1996; Gharagozlou et al. 2003). It is important to note that, having mixed agonist/antagonist 
properties, butorphanol intake might precipitate withdrawal symptoms in individuals maintained on 
higher efficacy opioids (WHO 2006). 
 
For isotonitazene (6), the pharmacological parameters found in the MOR-βarr2 assay (EC50 = 6.64 nM 
and Emax = 159%) are in line with previously published values from our group (Blanckaert & Cannaert et 
al. 2020). Isotonitazene was found to be two times more potent than fentanyl and almost twice as 
efficacious in recruiting mini-Gi. A recent cluster of deaths in the US in which this opioid was identified, 
can likely be attributed to the very high potency and efficacy of this compound (Krotulski, Papsun, et 
al. 2019, 2020; Krotulski and Logan 2019). Whereas a translation from in vitro data to the in vivo 
biological effect remains subject to complex pharmacodynamic and pharmacokinetic processes, it is 
interesting to note that isotonitazene concentrations reported in these deaths (0.4-9.5 ng/mL or 0.97-
23 nM in blood) are roughly in the same range as the in vitro EC50 values found here (6.64 nM for βarr2; 
16.3 nM for mini-Gi). However, it must be stressed that it is difficult to link systemic concentrations of 
centrally active drugs with those in the central nervous system – a critical parameter is e.g. passage 
through the blood-brain barrier (Kalvass et al. 2007). Furthermore, in the context of opioid use, the 
aspect of tolerance greatly hampers the interpretation of in vivo drug concentrations. In the cases 
reported by Krotulski et al., a history of heroin use was reported among several of the individuals, 
requiring opioid tolerance to be considered when aiming at interpreting the reported concentrations. 
In addition, other variables must also be taken into account, such as metabolic stability, conversion to 
potentially active metabolites and poly-drug use.  
 
Mitragynine (7) and 7-OH-mitragynine (8) are the primary psychoactive alkaloids in the tropical plant 
Mitragyna speciosa, colloquially known as kratom. Whereas kratom has a long history of traditional 
use in Southeast Asia, its worldwide recreational misuse has been on the rise in the recent years (DEA 
2019; Ventura et al. 2018). Our mini-Gi data confirm the observation by others that mitragynine is less 
potent than its metabolite 7-OH-mitragynine, suggesting an important role for this metabolic 
conversion in the in vivo effects induced by mitragynine (Kruegel & Gassaway et al. 2016, Kruegel & 
Uprety et al. 2019; Takayama 2004). This, combined with other factors, additionally complicates the 
interpretation of mitragynine concentrations in forensic casework (Kruegel & Uprety et al. 2019; 
Papsun et al. 2019). The in vitro pharmacology of mitragynine at MOR has furthermore been reported 
to be highly species-dependent. For example, Kruegel & Gassaway et al. (2016) showed that 
mitragynine (but not 7-OH-mitragynine) acts as a competitive antagonist at murine MOR, whereas 
weak partial agonism was observed at human MOR. Our results at human MOR support this, as both 
mitragynine and its 7-OH metabolite are partial agonists when compared to hydromorphone (Emax < 
100%; Table 1). In terms of potency at human MOR, however, Kruegel & Gassaway et al. (2016) 
reported lower EC50 values for mitragynine and 7-OH-mitragynine using a G protein bioluminescence 
resonance energy transfer (BRET) assay (EC50 = 339 ± 178 nM and 34.5 ± 4.5 nM, respectively) than 
those observed with our MOR-mini-Gi assay (EC50 = 1089 nM for (7) and 191 nM for (8)). These 
apparent discrepancies may be the result of interassay differences. Interestingly, the authors 
additionally reported “extremely weak” β-arrestin recruitment (even in the presence of GRK2, known 
to enhance coupling to β-arrestins) upon MOR activation by mitragynine and 7-OH-mitragynine in a 
BRET assay, stating strong qualitative bias in favor of G protein signaling (Kruegel & Gassaway et al. 
2016). Using our MOR-βarr2 assay, the level of β-arrestin 2 recruitment was sufficient for both 
compounds to allow quantification of a possible bias (as compared to mini-Gi recruitment). No 
significant difference was found when compared to the unbiased reference hydromorphone. This 
clearly underscores the difficulty in comparing results obtained with different assays and highlights the 
importance of a comparative evaluation of a diverse set of compounds, using the same set-up, as 
applied in this study. In the current study, mitragynine and its 7-hydroxy metabolite are between 5-54 
times less potent than fentanyl, depending on the studied pathway. 
 
MT-45 (9) was initially studied as an analgesic in the 1970s (Haruki et al. 1975; Natsuka et al. 1975, 
1987) and was first detected in Sweden in late 2013. Following Sweden’s ban on AH-7921, 28 deaths 
had been associated with MT-45 use in a nine-month period between November 2013 and July 2014 
(EMCDDA 2015). In one death in which MT-45 was the only substance involved, a blood concentration 
of 802 ng/mL (2300 nM) was reported (Logan et al. 2017). Taking into account the aforementioned 
caveats, this concentration approaches the estimated in vitro EC80 value of MT-45 (2100 nM for βarr2 
and 2896 nM for mini-Gi). In another case, a lower concentration of MT-45 was found in a decedent’s 
blood (520 ng/mL or 1492 nM), albeit in combination with a therapeutic etizolam concentration 
(Papsun et al. 2016). The in vitro potency (EC50) of MT-45 was previously reported to be 124 ± 24 nM 
in a (35S)GTPγS assay monitoring G protein recruitment to activated murine MOR (Baumann et al. 
2018). A similar potency (182 nM; 95% CI 77-426 nM) was found using a dynamic mass redistribution 
assay (Bilel et al. 2020). Remarkably, in a study assessing activation of the G protein pathway via 
monitoring of the inhibition of forskolin-stimulated cAMP accumulation, an approximately 10-fold 
higher value (EC50 = 1300 nM) was reported (Baptista-Hon et al. 2020). In the MOR-mini-Gi assay we 
applied, in which a receptor-proximal event is monitored, we found a somewhat intermediate potency 
(EC50 = 724 nM). The MOR-βarr2 assay deployed here, too, yielded an intermediate potency for MT-45 
(EC50 = 525 nM). Interestingly, using another enzyme complementation assay (PathHunter®, DiscoverX) 
to assess βarr2 recruitment to MOR, a ~40-fold lower EC50 value (23 µM) was reported by Baptista-
Hon et al. (2020). Noteworthy in this context is that application of this same PathHunter® assay also 
yielded a relatively high EC50 value for fentanyl (120 nM (Baptista-Hon et al. 2020)), whereas we found 
an approximately 8-fold lower value (EC50 = 14.3 nM) with the MOR-βarr2 system. Again, this stresses 
the importance of mentioning the applied assay format when making statements on a compound’s 
potency and/or efficacy. In our assay systems, MT-45 is 22-37 times less potent than fentanyl. Whereas 
MT-45 has now been listed in Schedule I of the 1961 Convention, different analogues continue to 
appear on the market, stressing the importance of continued research into MT-45 and its derivatives 
(Baptista-Hon et al. 2020; Cannaert & Hulpia et al. 2020).  
 
Piperidylthiambutene (10) (piperidinohton) has been studied for its potential as analgesic (Adamson 
1951; Adamson and Green 1950; Green 1953) and antitussive drug (Kase et al. 1955; Kimura, Ogawa, 
and Yabuuchi 1959), but was never marketed. Its potency at MOR (EC50 = 180 nM for βarr2; 443 nM 
for mini-Gi) is about 13-fold lower than that of fentanyl. Perhaps more reason for concern, however, 
is this compound’s relatively high efficacy, particularly in terms of mini-Gi recruitment (Emax = 349% for 
mini-Gi; 130% for βarr2). At present, relatively little is known about the abuse of piperidylthiambutene 
and its structural analogues. A recent study by Arillotta & Schifano et al. (2020) used a web crawler 
tool to better understand trends regarding opioid use in online drug user platforms. 
Piperidylthiambutene was amongst the 136 non-fentanyl opioids of which open discussions among 
psychonauts were picked up, potentially reflecting interest in the drug (Arillotta & Schifano et al. 2020). 
The first formal identification of piperidylthiambutene in Europe was reported early 2019, in a powder 
purchased from the Internet (EMCDDA 2019c; NFL Ljubljana 2019b). Later that year, it was also seized 
in the US (Krotulski, Fogarty, and Logan 2019c). In the first quarter of 2020, piperidylthiambutene has 
been identified in 4 different cases in the US, potentially indicating its increasing use (Krotulski, Mohr 
and Logan 2020). An interesting and perhaps worrying observation is that, in all 4 cases, 
piperidylthiambutene was identified together with the highly potent and efficacious drug 
isotonitazene (Krotulski, Mohr and Logan 2020).  
 
Based on its structural similarity to tricyclic antidepressants, tianeptine (11) may seem the odd one out 
within this panel of opioid NPS. Tianeptine (e.g. Stablon®, Coaxil®) is prescribed for the treatment of 
depression and anxiety in several countries in Europe, Asia and Latin America. However, studies have 
shown that the pharmacology of tianeptine is markedly different from that of most antidepressants, 
the behavioral-inducing characteristics being mediated by its agonistic activity at MOR (Gassaway et 
al. 2014; Samuels et al. 2017). A G protein BRET and cAMP inhibition assay resulted in EC50 values of 
194 ± 70 nM and 151 ± 45 nM, respectively, at human MOR (Gassaway et al. 2014). Interestingly, the 
estimated EC50 value obtained in our MOR-mini-Gi assay was at least 50-fold higher, indicating a lower 
potency than initially reported. Despite this low potency (> 200 times less potent than fentanyl), the 
unregulated use of tianeptine as a research chemical appears to be on the rise (El Zahran et al. 2018). 
When sold as dietary supplement, its use might even be a blind spot for early warning systems (Evans-
Brown and Sedefov 2018; Griffiths, Evans-Brown, and Sedefov 2013). However, as several case reports 
highlight the danger of the potentially fatal misuse of tianeptine (Bakota et al. 2018; Dempsey et al. 
2017; Proença et al. 2007; Rushton et al. 2020), increasing awareness is of critical importance.  
  
Conclusion 
Following strengthened control measures targeting fentanyl and fentanyl analogues, non-fentanyl 
opioids are increasingly (re)appearing on the illicit market. This study is the first to systematically 
evaluate the in vitro biological activity of a diverse panel of emerging non-fentanyl opioid NPS at MOR. 
Pharmacological profiling of such novel substances is crucial to make a realistic estimation of the 
potential danger their use might bring along. Considering the high potencies and efficacies of many 
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Fig. 1 Structures of the studied non-fentanyl opioid new psychoactive substances: (1) 2-methyl-AP-
237; (2) AP-237; (3) bromadol; (4) brorphine; (5) butorphanol; (6) isotonitazene; (7) mitragynine; (8) 
7-OH-mitragynine; (9) MT-45; (10) piperidylthiambutene; and (11) tianeptine. The grey panel shows 
(A) hydromorphone, the reference compound in this study, and (B) fentanyl, for comparison. 
 
  
Fig. 2 Activation profiles obtained for A. the 11 studied non-fentanyl opioid new psychoactive 
substances; and B. the reference compound, hydromorphone, and fentanyl. Data are presented as 
mean receptor activation ± standard error of the mean (SEM) and are normalized to the Emax of 
hydromorphone (= 100%). Note the differences in scale of the y-axes. Black triangles, mini-Gi 







Fig. 3 Quantitative bias plot. Δlog(Emax/EC50)βarr2 - Δlog(Emax/EC50)mini-Gi is plotted as bias factor ± SEM. A 
bias factor above zero indicates bias towards the β-arrestin 2 pathway, whereas a negative value 
implies bias towards mini-Gi recruitment. None of the tested compounds showed statistically 




Table 1 Potency (EC50) and efficacy (Emax, relative to hydromorphone) values (with 95% confidence 
intervals) as obtained in the µ-opioid receptor activation assays monitoring either β-arrestin 2 or mini-
Gi recruitment. (1) 2-methyl-AP-237; (2) AP-237; (3) bromadol; (4) brorphine; (5) butorphanol; (6) 
isotonitazene; (7) mitragynine; (8) 7-OH-mitragynine; (9) MT-45; (10) piperidylthiambutene; (11) 
tianeptine; (A) hydromorphone; and (B) fentanyl.  
 
 (*) Maximum receptor activation seen at 100 µM. EC50 values to be interpreted with caution.  
 
 
 β-arrestin 2 Mini-Gi 
  EC50 (nM) Emax (%)  EC50 (nM)  Emax (%)  
1. 2-methyl-AP-237  2229 (1267-4061)  109 (95-124) 2229 (1300-3932)  142 (126-161) 
2. AP-237  > 3x104* 69.3* (58.8-85.4) > 8x103* 52.1* (37.7-90.0) 
3. Bromadol 1.89 (1.23-2.93) 182 (172-192) 3.04 (1.48-6.28) 462 (414-512) 
4. Brorphine 31.1 (20.7-47.0) 226 (207-246) 106 (84.1-134) 385 (363-408) 
5. Butorphanol 12.1 (6.66-22.9) 43.8 (40.1-47.5) 13.5 (1.95-104) 30.9 (23.5-39.3) 
6. Isotonitazene 6.64 (2.84-15.0) 159 (140-178) 16.3 (10.6-25.5) 484 (444-525) 
7. Mitragynine 773 (513-1148) 19.2 (17.4-21.1) 1089 (280-4442) 29.7 (21.6-41.8) 
8. 7-OH-mitragynine 369 (220-612) 43.5 (39.9-47.3) 191 (92.4-415) 52.2 (46.1-58.9) 
9. MT-45 525 (335-811) 108 (97-120) 724 (432-1176) 163 (145-183) 
10. Piperidylthiambutene 180 (63.0-530) 130 (105-157) 443 (284-680) 349 (319-381) 
11. Tianeptine 3262 (2543-4189) 166 (157-176) > 1x104*  266* (243-292) 
A. Hydromorphone  51.0 (36.5-70.5) 100 (94.0-105) 44.0 (22.2-83.5) 100 (89.1-111) 
B. Fentanyl 14.3 (11.3-18.1) 163 (157-169) 32.7 (23.3-45.8) 284 (269-300) 
